Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.55 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.54 |
| ▸ | FEN1 | P39748 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | GCK | P35557 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.52 |
| ▸ | FABP1 | P07148 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14009963 | 0.88 | HDAC8 (0.52) | HDAC8AKR1C3NPC1LMNASMN1; SMN2 | |
| SCHEMBL3043303 | 0.87 | HDAC8 (0.61) | HDAC8AKR1C3NPC1LMNAPKM | |
| SCHEMBL13702268 | 0.85 | NPSR1 (0.61) | HDAC8AKR1C3NPC1LMNAPKM | |
| SCHEMBL8541406 | 0.84 | NPC1 (0.64) | NPC1LMNAPKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL10197594 | 0.83 | LMNA (0.58) | HDAC8NPC1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7053844 | 0.82 | HDAC8 (0.73) | HDAC8AKR1C3NPC1LMNAPKM | |
| SCHEMBL13701690 | 0.81 | SMPD1 (0.71) | LMNAALDH1A1 | |
| SCHEMBL13701741 | 0.81 | LMNA (0.60) | NPC1LMNASMN1; SMN2ALDH1A1KAT6A | |
| SCHEMBL21249304 | 0.81 | LMNA (0.58) | HDAC8NPC1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL21616256 | 0.81 | LMNA (0.48) | HDAC8NPC1LMNAALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | HDAC8 1490/4885AKR1C3 490/4885NPC1 1477/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | HDAC8 3426/4885AKR1C3 212/4885NPC1 4262/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | HDAC8 3010/4885AKR1C3 790/4885NPC1 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.